OsmoLax (Macrogol-3350)
macrogol-3350 1 g/g powder for oral liquid, 510 g · ORAL · PBS code 14341T
RESTRICTEDWhat it costs
AU$8.81 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-09-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Constipation
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
Patient must have malignant neoplasia.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Constipation
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
Patient must be paraplegic, quadriplegic or have severe neurogenic impairment of bowel function; AND
The condition must be unresponsive to other oral therapies.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Constipation
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
Patient must be receiving palliative care.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chronic constipation
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
The condition must be inadequately controlled with first line interventions such as bulk-forming agents.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Faecal impaction
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
The condition must be inadequately controlled with first line interventions such as bulk-forming agents.
Sponsor: Key Pharmaceuticals Pty Ltd ABN 21 001 215 130
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.